Guide Medicinal Product

Progress against AIDS with generic drugs: pharmaceutical companies

Following the interview of Dr. Nathalie Cugnardey, Medical Director Europe Mylan laboratories.

Why is the Mylan Lab involved so much in the fight against AIDS?

Dr Nathalie Cugnardey: Mylan has been particularly involved for 10 years in the fight against HIV / AIDS. Since 2003, Mylan has been providing quality active ingredients to generic antiretroviral manufacturers.

In 2007, the company began offering finished products and launched a range of pediatric and adult ARVs. Today, Mylan is widely respected for the quality, reliability and accessibility of its ARV franchise, which allows the laboratory to be a leading player in this sector or in the care of HIV / AIDS.

What types of actions have you taken to help developing countries?

Dr. NC: Mylan has proposed a number of ARV innovations in developing countries, such as the production of packaged "combo packs" and new heat-resistant ARVs. In addition, Mylan is one of the world leaders in the production of pediatric formulations.

In 2012, thanks to these innovations, we provided 43 ARV drugs in more than 120 countries. Today, these products help around 40% of people receiving HIV / AIDS treatment in developing countries.

Mylan's progress in the fight against HIV / AIDS also reflects its strong partnerships with many organizations that share its humanitarian goals. Many of these organizations, such as the Bill and Melinda Gates Foundation and the Clinton Initiative (or CHAI), focus in part on obtaining a reliable and accessible ARV supply, and have found in our laboratory a partner of choice .

Does the lab sponsor events that raise awareness and raise funds for important causes?

Dr. NC: Yes. So the World Team Tennis's Smash Hits competition, supports several charities, like the Elton John Foundation Against AIDS. In addition, the lab is a member of the Global Business Coalition on HIV / AIDS, Tuberculosis and Malaria (GBC), the leading business organization leading the fight against illness and discrimination in the workplace that can to accompany.
Mylan has also entered into licensing agreements with Bristol-Myers Squibb, Gilead Sciences, Merck and ViiV, enabling it to produce and market generic versions of many of its ARVs in developing countries.

Mylan's commitment in this fight demonstrates that its goal is to go beyond the mere production of generic drugs, but also to address unmet medical needs and ensure accessibility to drugs.

To read: A generic medicine is not quite identical to the original medicine (princeps) ...

Popular Posts

Category Guide Medicinal Product, Next Article

Self-medication: the advice of a doctor - Guide Medicinal Product
Guide Medicinal Product

Self-medication: the advice of a doctor

Dr. Loïc Etienne, emergency physician and inventor of the tool for analyzing symptoms on the web, e-doctor, gives his advice on self-medication. As a doctor, what is your view on self-medication? Dr. Loïc Etienne: I advocate for over 20 years self-medication, it's absurd to be against. It is a natural act to want to relieve suffering as quickly as possible.
Read More
Drugs: why so many problems?  : The steps in the development of a drug - Guide Medicinal Product
Guide Medicinal Product

Drugs: why so many problems? : The steps in the development of a drug

For the development and future commercialization of a drug, there are three phases of clinical trials before the MA. The phases of clinical trials on people are only started if the results of the animal testing upstream were found to be positive. > Phase 1: We validate the tolerance. It involves administering increasing amounts of the new molecule to healthy volunteers (under close surveillance) to evaluate the broad lines of product tolerance and pharmacological activity
Read More
Anticoagulant: What are the anticoagulants? - Guide Medicinal Product
Guide Medicinal Product

Anticoagulant: What are the anticoagulants?

Vitamin K antagonists are anticoagulant drugs that thin the blood, or more accurately, that prevent the formation of clots and promote the resorption of those that already exist. But note that there are new anticoagulant treatments that are not antivitamins K, read further what you need to know about what is called NACO
Read More
Anticoagulant: all you need to know - Guide Medicinal Product
Guide Medicinal Product

Anticoagulant: all you need to know

In France, more than 600, 000 people take anticoagulant treatments. These anticoagulant treatments are intended to thin the blood to prevent clot formation, and help prevent serious cardiovascular events. The formation of a clot is very dangerous, because it could more or less obstruct a vessel and thus impede the blood circulation
Read More